A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Item 1. Business. DBV Technologies is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. Our therapeutic approach is based on epicutaneous immunotherapy, or EPIT, our proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). We have generated significant data demonstrating that Viaskin’s mechanism of action is novel and differentiated. Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 5.5M | - | - | - | - | - |
| Net Income | -125M | -114M | -73M | -96M | -98M | -160M |
| EPS | $-1.04 | $-1.17 | $-0.76 | $-1.24 | $-1.78 | $-2.95 |
| Free Cash Flow | -98M | -107M | -80M | -56M | -109M | -168M |
| ROIC | -90.0% | -336.3% | -51.9% | -49.6% | -98.0% | -77.2% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 1.40 | 0.00 | -0.00 | 0.01 | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -126M | -117M | -76M | -97M | -99M | -159M |
| Operating Margin | -2287.6% | - | - | - | - | - |
| ROE | -236.8% | -136.0% | -43.5% | -65.6% | -64.2% | -80.0% |
| Shares Outstanding | 169M | 97M | 96M | 78M | 55M | 54M |
DBV Technologies S.A. passes 0 of 9 quality checks, indicating weak fundamentals.
DBV Technologies S.A. (DBVT) has a 5-year average return on invested capital (ROIC) of -69.2%. This is below average and may indicate limited pricing power.
DBV Technologies S.A. (DBVT) has a market capitalization of $3.7B. It is classified as a mid-cap stock.
DBV Technologies S.A. (DBVT) does not currently pay a regular dividend.
DBV Technologies S.A. (DBVT) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
DBV Technologies S.A. (DBVT) generated $-107 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
DBV Technologies S.A. (DBVT) has a debt-to-equity ratio of 1.40. This indicates moderate leverage.
DBV Technologies S.A. (DBVT) reported earnings per share (EPS) of $-1.17 in its most recent fiscal year.
DBV Technologies S.A. (DBVT) has a return on equity (ROE) of -136.0%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 10 years of financial data for DBV Technologies S.A. (DBVT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
DBV Technologies S.A. (DBVT) has a book value per share of $0.28, based on its most recent annual SEC filing.